TG Therapeutics | TGTX - Net Income


TG Therapeutics reported $19.78M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
AbbVie USD 695M 1.12B Mar/2026
Alaunos Therapeutics USD -1.01M 153K Mar/2026
Amgen USD 1.82B 486M Mar/2026
Ardelyx USD -407K 562K Dec/2025
Arrowhead Research USD -132.73M 163.54M Mar/2026
Bayer EUR 2.76B 6.52B Mar/2026
Biogen USD 319.5M 368.4M Mar/2026
Corcept Therapeutics USD -31.76M 56.05M Mar/2026
Curis USD 19.36M 31.16M Dec/2025
Gilead Sciences USD 2.02B 162M Mar/2026
J&J USD 5.24B 119M Mar/2026
Karyopharm Therapeutics USD -102.2M 71.42M Dec/2025
Novartis USD 3.16B 747M Mar/2026
Novavax USD 17.53M 219.91M Dec/2025
PTC Therapeutics USD -2.81M 132.16M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 727.2M 117.4M Mar/2026
Roche Holding CHF 5.47B 1.76B Dec/2025
TG Therapeutics USD 19.78M 3.26M Mar/2026
Verastem USD -32.92M 24.66M Dec/2025
Vertex Pharmaceuticals USD 1.03B 159.7M Mar/2026